Traders should monitor FDA acceptance of the NDA for filing and any subsequent review milestones. The Rare Pediatric Disease PRV, if awarded, could be monetized for tens to hundreds of millions of dollars, providing non-dilutive capital. Key risk: FDA could issue a Complete Response Letter (CRL) on safety/efficacy or CMC grounds, which would be highly bearish for this single-asset company.
Price Chart
Executive Summary
Monopar Therapeutics initiated a rolling NDA submission to the FDA for ALXN1840 (tiomolibdate choline), a first-in-class ATC activator for Wilson disease. The FDA authorized the rolling submission, and the first sections have been submitted; ALXN1840 also received Rare Pediatric Disease designation in June 2026, which could yield a Priority Review Voucher upon approval. This is a significant regulatory milestone for a late-stage program with positive Phase 3 data, but approval is not guaranteed and the company remains pre-revenue.
Key Facts
- Monopar initiated rolling NDA submission to FDA for ALXN1840 (tiomolibdate choline) for Wilson disease
- FDA authorized rolling submission; first completed sections submitted
- ALXN1840 received Rare Pediatric Disease designation in June 2026, potentially qualifying for a Priority Review Voucher
- ALXN1840 has Fast Track and Orphan Drug designations
- Pivotal Phase 3 trial met primary endpoint: rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks
- Safety profile based on 645 patient-years of follow-up in 266 patients
- If approved, ALXN1840 would be the first novel-mechanism therapy for Wilson disease in decades in the U.S.
Financial Impact
Pre-revenue clinical-stage biotech; potential value hinges on NDA approval and potential PRV monetization. No financial figures disclosed.
Risk Factors
- FDA may not accept the NDA for filing or may issue a CRL
- Wilson disease is a niche indication with limited patient population (~1 in 30,000 worldwide)
- Monopar is pre-revenue and will need additional financing to support commercialization if approved
- Rare Pediatric Disease PRV program authorization and availability are not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3331283 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $70.54 (+11.35%) |
Oct 1, 2026 25d ago | 144 | $77.97 | awaiting T+60 | — | $70.54 (−9.53%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $70.54 (−36.98%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $70.54 (−36.96%) |
Aug 25, 2026 8w ago | 144 | $113.72 | awaiting T+60 | — | $70.54 (−37.97%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $70.54 (−38.61%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $70.54 (−38.61%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $70.54 (−37.29%) |
Jul 22, 2026 13w ago | Press Release | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $70.54 (−37.29%) |
Jun 30, 2026 16w ago | 8-K | $92.59 $89.38 | ▼ −3.47% | ▼ −7.03% | $70.54 (−23.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers